A new study for people with extensive-stage small cell lung cancer using a study drug plus chemo
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (the cancer has spread beyond the lung).
- You have not had any prior treatment for the extensive stage of your cancer.
- If you previously had treatment for limited-stage small cell lung cancer, it must have been at least 6 months ago.
- You have at least one measurable tumor that can be tracked by scans.
- You are in good overall health (able to do daily activities) with a performance status of 0 or 1.
- Your organs (like kidneys, liver, and bone marrow) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
Hear when a new Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.